PharmaCyte Biotech CEO Interviewed Live During Marcum MicroCap Conference
June 20 2016 - 9:00AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today announced that Kenneth L.
Waggoner, the Chief Executive Officer of PharmaCyte, was
interviewed by Stock News Now (SNN) at the 5th Annual Marcum
MicroCap Conference in New York City. The SNNLive video interview
can be viewed by clicking on the following link:
www.PharmaCyte.com/Media.
During his interview, Mr. Waggoner describes how
PharmaCyte plans to use its live cell encapsulation technology,
known as Cell-in-a-Box®, for the development of treatments for
locally advanced, inoperable pancreatic cancer and for Type 1 and
insulin-dependent Type 2 diabetes. Mr. Waggoner also discusses the
mechanism of action PharmaCyte uses to treat cancerous tumors and
talks about PharmaCyte’s plans to begin a Phase 2b clinical trial
in patients with locally advanced, inoperable pancreatic cancer.
That trial is planned to start in Q4 2016.
In discussing PharmaCyte’s efforts to develop a
treatment for diabetes, Mr. Waggoner talks about the preclinical
studies that are being conducted concurrently by several renowned
experts in the field of diabetes in various countries around the
globe. All of these experts are members of PharmaCyte’s
International Diabetes Consortium. Mr. Waggoner also explains that
by conducting their studies as part of a consortium, rather than
sequentially, the overall treatment development timeline has been
shortened considerably. This will allow PharmaCyte to potentially
begin a clinical trial in diabetes as early as late 2017.
About PharmaCyte BiotechPharmaCyte Biotech is a
clinical stage biotechnology company developing and preparing to
commercialize treatments for cancer and diabetes based upon a
proprietary cellulose-based live cell encapsulation technology
known as “Cell-in-a-Box®.” This technology will be used as a
platform upon which treatments for several types of cancer and
diabetes are being developed. PharmaCyte’s treatment for cancer
involves encapsulating genetically modified human cells that
convert an inactive chemotherapy drug into its active or
“cancer-killing” form. These encapsulated cells are placed as close
to a cancerous tumor as possible. Once implanted in a patient, a
chemotherapy drug which needs to be activated in the body
(ifosfamide) is then given intravenously at one-third the normal
dose. The ifosfamide is carried by the circulatory system to where
the encapsulated cells have been placed. When the ifosfamide, which
is normally activated in the liver, comes in contact with the
encapsulated cells, activation of the chemotherapy drug takes place
at the source of the cancer without any side effects from the
chemotherapy. This “targeted chemotherapy” has proven remarkably
effective and safe to use in past clinical trials.
In addition to developing a novel treatment for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and insulin-dependent Type 2 diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology.
Safe Harbor This press release may contain
forward-looking statements regarding PharmaCyte Biotech and its
future events and results that involve inherent risks and
uncertainties. The words "anticipate", "believe", "estimate",
"expect", "intend", "plan" and similar expressions, as they relate
to PharmaCyte or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte, could cause actual results to
differ materially from those set forth in the forward-looking
statements. They include PharmaCyte's ability to continue as a
going concern, delays or unsuccessful results in preclinical and
clinical trials, flaws or defects regarding its product candidates,
changes in relevant legislation or regulatory requirements,
uncertainty of protection of PharmaCyte’s intellectual property and
PharmaCyte’s continued ability to raise capital. PharmaCyte does
not assume any obligation to update any of these forward-looking
statements.
More information about PharmaCyte can be found
at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com